黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

The oncogenic transcription factor FUS-CHOP can undergo nuclear liquid-liquid phase separation

J Cell Sci. 2021-09; 
Izzy Owen, Debra Yee, Hala Wyne, Theodora Myrto Perdikari, Victoria Johnson, Jeremy Smyth, Robert Kortum, Nicolas L Fawzi, Frank Shewmaker
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis FUS-CHOP type I and type II genes were synthesized by Genscript (Piscataway, NJ, USA) ... Gels were transferred using an eBlot L1 (L00686; GenScript) onto nitrocellulose membranes (1620112; Bio-Rad Laboratories) Get A Quote

摘要

Myxoid liposarcoma is caused by a chromosomal translocation resulting in a fusion protein comprised of the N terminus of FUS (fused in sarcoma) and the full-length transcription factor CHOP (CCAAT/enhancer-binding protein homologous protein, also known as DDIT3). FUS functions in RNA metabolism, and CHOP is a stress-induced transcription factor. The FUS-CHOP fusion protein causes unique gene expression and oncogenic transformation. Although it is clear that the FUS segment is required for oncogenic transformation, the mechanism of FUS-CHOP-induced transcriptional activation is unknown. Recently, some transcription factors and super enhancers have been proposed to undergo liquid-liquid phase separation and form ... More

关键词

CHOP, FUS, Liquid–liquid phase separation, Oncogenic fusion protein, Transcriptional activation